EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Antidepressants for pain management in adults with chronic pain: a network meta-analysis

Hollie Birkinshaw iD, Claire Friedrich iD, Peter Cole iD, Christopher Eccleston iD, Marc Serfaty iD, Gavin Stewart iD, Simon White iD, Andrew Moore iD, David Phillippo iD, Tamar Pincus iD

Health Technology Assessment · 2024-10 · 1-155

DOI: 10.3310/mkrt2948 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Health Technology Assessment, 2024-10. Verfasst von Hollie Birkinshaw und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, University of Southampton, Southampton, UK. Hauptthemen laut MEDLINE: Antidepressive Agents, Chronic Pain, Pain Management. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic pain is common and costly. Antidepressants are prescribed to reduce pain. However, there has not been a network meta-analysis examining all antidepressants across all chronic pain conditions, so effectiveness and safety for most antidepressants for pain conditions remain unknown.

Objective

To assess the efficacy and safety of antidepressants for chronic pain (except headache) in adults. Our primary outcomes were as follows: substantial pain relief (50%), pain intensity, mood and adverse events. Our secondary outcomes were as follows: moderate pain relief (30%), physical function, sleep, quality of life, Patient Global Impression of Change, serious adverse events and withdrawal.

Design

This was a systematic review with a network meta-analysis. We searched CENTRAL, MEDLINE, EMBASE, CINAHL, LILACS, AMED and PsycINFO databases for randomised controlled trials of antidepressants for chronic pain conditions up until 4 January 2022. The review was registered in PROSPERO (CRD42020171855), and the protocol was published in the Cochrane Library (https://doi.org/10.1002/14651858.CD014682).

Setting

We analysed trials from all settings.

Participants

We included trials in which participants had chronic pain, defined as longer than 3 months, from any condition excluding headache.

Interventions

We included all antidepressants. Main outcome measures Our primary outcome was substantial pain relief, defined as a reduction ˃ 50%. We also measured pain intensity, mood and adverse events. Secondary measures included moderate pain relief (above 30% reduction), physical function, sleep, quality of life, Global Impression of Change, serious adverse events, and withdrawal from trial.

Results

We identified 176 studies with a total of 28,664 participants. Most studies were placebo-controlled ( n = 83) and parallel armed ( n = 141). The most common pain conditions examined were fibromyalgia (59 studies), neuropathic pain (49 studies) and musculoskeletal pain (40 studies). The average length of randomised controlled trials was 10 weeks. Most studies measured short-term outcomes only and excluded people with low mood and other mental health conditions. Across efficacy outcomes, duloxetine was consistently the highest-ranked antidepressant with moderate- to high-certainty evidence. Standard dose was equally efficacious as high dose for the majority of outcomes. Milnacipran was often ranked as the next most efficacious antidepressant, although the certainty of evidence was lower than that for duloxetine. There was insufficient evidence to draw robust conclusions for the efficacy and safety of any other antidepressant for chronic pain.

Limitations

The evidence for antidepressants other than duloxetine is poor. For duloxetine, it is not clear whether the effect applies to groups with both pain and low mood, since these groups were excluded from trials. There is also insufficient evidence on long-term outcomes and on adverse effects.

Conclusions

There is only reliable evidence for duloxetine in the treatment of chronic pain. Duloxetine was moderately efficacious across all outcomes at standard dose. There is also promising evidence for milnacipran, although further high-quality research is needed to be confident in these conclusions. Data for all other antidepressants were of low certainty. However, the findings should not be read as an encouragement to prescribe antidepressants where other non-pharmacological intervention could be equally effective, especially in the absence of good evidence on side effects and safety. Future work There is a need for large, methodologically sound trials testing the effectiveness of antidepressants for chronic pain. These trials should examine long-term outcomes (> 6 months) and include people with low mood. There should also be better reporting of adverse events, tolerance of drugs, and long-term compliance. Study registration This study is registered as PROSPERO CRD42020171855. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR128782) and is published in full in Health Technology Assessment ; Vol. 28, No. 62. See the NIHR Funding and Awards website for further award information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsChronic PainPain ManagementAdultHumansQuality of LifeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

ADULTANTIDEPRESSIVE AGENTSCHRONIC PAINDEPRESSIONDULOXETINE HYDROCHLORIDEFIBROMYALGIAHUMANSMETA-ANALYSISMILNACIPRANMIRTAZAPINEQUALITY OF LIFERANDOMIZED CONTROLLED TRIALSSYSTEMATIC REVIEW

Substanzen

Antidepressive Agents

Autor:innen und Institutionen

  • Department of Psychology, University of Southampton, Southampton, UK.
  • Oxford Pain Relief Unit, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK.
  • Centre for Pain Research, University of Bath, Bath, UK.
  • University College London, London, UK.
  • Newcastle University, Newcastle upon Tyne, UK.
  • School of Pharmacy and Bioengineering, Keele University, Keele, UK.

ORCID-Profile: Hollie Birkinshaw, Claire Friedrich, Peter Cole, Christopher Eccleston, Marc Serfaty, Gavin Stewart, Simon White, Andrew Moore, David Phillippo, Tamar Pincus

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Birkinshaw, H., Friedrich, C., Cole, P., Eccleston, C., Serfaty, M., Stewart, G., White, S., Moore, A., Phillippo, D., & Pincus, T. (2024). Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Health Technology Assessment, 1-155. https://doi.org/10.3310/mkrt2948

Vancouver

Birkinshaw H, Friedrich C, Cole P, Eccleston C, Serfaty M, Stewart G, et al. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Health Technology Assessment. 2024:1-155. doi:10.3310/mkrt2948

BibTeX
@article{Birkinshaw2024,
  author = {Birkinshaw, Hollie and Friedrich, Claire and Cole, Peter and Eccleston, Christopher and Serfaty, Marc and Stewart, Gavin and White, Simon and Moore, Andrew and Phillippo, David and Pincus, Tamar},
  title = {Antidepressants for pain management in adults with chronic pain: a network meta-analysis},
  journal = {Health Technology Assessment},
  year = {2024},
  pages = {1--155},
  doi = {10.3310/mkrt2948}
}
Kostenlos starten →